Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Sell
14
GRDN Quote, Financials, Valuation and Earnings
Last price:
$20.14
Seasonality move
:
--
Day range:
$19.91 - $20.62
52-week range:
$14.16 - $26.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.99x
P/B ratio:
8.24x
Volume:
191.6K
Avg. volume:
327K
1-year change:
--
Market cap:
$1.3B
Revenue:
$1.2B
EPS (TTM):
-$1.49
Analysts' Opinion
-
Consensus RatingGuardian Pharmacy Services has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $27.33, Guardian Pharmacy Services has an estimated upside of 34.51% from its current price of $20.32.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $26.00 representing 100% downside risk from its current price of $20.32.
Fair Value
-
According to the consensus of 2 analysts, Guardian Pharmacy Services has 34.51% upside to fair value with a price target of $27.33 per share.
GRDN vs. S&P 500
-
Over the past 5 trading days, Guardian Pharmacy Services has overperformed the S&P 500 by 2.44% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Guardian Pharmacy Services does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Guardian Pharmacy Services has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Guardian Pharmacy Services reported revenues of $329.3M.
Earnings Growth
-
Guardian Pharmacy Services earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Guardian Pharmacy Services reported earnings per share of $0.15.
Enterprise value:
1.3B
EV / Invested capital:
7.84x
Price / LTM sales:
0.99x
EV / EBIT:
--
EV / Revenue:
1.00x
PEG ratio (5yr expected):
--
EV / Free cash flow:
26.44x
Price / Operating cash flow:
26.20x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$253.6M
Return On Assets:
-24.66%
Net Income Margin (TTM):
-6.29%
Return On Equity:
-71.46%
Return On Invested Capital:
-56.09%
Operating Margin:
3.95%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $894M | $1.1B | $1.3B | $275.4M | $329.3M | |
| Gross Profit | $181.5M | $212.2M | $253.6M | $55.1M | $64.3M | |
| Operating Income | $25M | $42.4M | -$57.8M | $7.9M | $13M | |
| EBITDA | $41.4M | $60.6M | -$37.5M | $12.6M | $18.5M | |
| Diluted EPS | $0.14 | $0.35 | -$1.49 | -- | $0.15 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $92.2M | -- | $118.4M | -- | $166M | |
| Total Assets | $214.6M | -- | $262M | -- | $334M | |
| Current Liabilities | $84.5M | -- | $108.6M | -- | $145.3M | |
| Total Liabilities | $152.7M | -- | $189.3M | -- | $170.8M | |
| Total Equity | $61.9M | -- | $72.7M | -- | $163.2M | |
| Total Debt | $34.5M | -- | $26.9M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | $61.9M | $66.9M | $8.7M | $17.6M | |
| Cash From Investing | -- | -$13.4M | -$32.4M | -$3.6M | -$5.5M | |
| Cash From Financing | -- | -$48.9M | -$20.7M | -$5.6M | -$2.7M | |
| Free Cash Flow | $42.1M | $47.4M | $48.4M | $5M | $11.7M | |
GRDN
Sector
Market Cap
$1.3B
$256M
Price % of 52-Week High
75.51%
74.38%
Dividend Yield
0%
0%
Shareholder Yield
--
2.87%
1-Year Price Total Return
--
-10.24%
Beta (5-Year)
--
0.395
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
-35.5%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$19.95
200-day SMA
Buy
Level
$0.00
Bollinger Bands (100)
Sell
Level
19.75 - 23.83
Chaikin Money Flow
Buy
Level
332.6K
20-day SMA
Sell
Level
$20.74
Relative Strength Index (RSI14)
Sell
Level
40.33
ADX Line
Sell
Level
26.61
Williams %R
Neutral
Level
-63.2588
50-day SMA
Sell
Level
$22.92
MACD (12, 26)
Sell
Level
-0.89
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Sell
Level
-66K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.7864)
Sell
CA Score
(Annual)
Level (-0.9841)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Sell
Ohlson Score
Level (1.8943)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
Stock Forecast FAQ
In the current month, GRDN has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GRDN average analyst price target in the past 3 months is $27.33.
-
Where Will Guardian Pharmacy Services Stock Be In 1 Year?
According to analysts, the consensus estimate is that Guardian Pharmacy Services share price will rise to $27.33 per share over the next 12 months.
-
What Do Analysts Say About Guardian Pharmacy Services?
Analysts are divided on their view about Guardian Pharmacy Services share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Guardian Pharmacy Services is a Sell and believe this share price will drop from its current level to $26.00.
-
What Is Guardian Pharmacy Services's Price Target?
The price target for Guardian Pharmacy Services over the next 1-year time period is forecast to be $27.33 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GRDN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Guardian Pharmacy Services is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GRDN?
You can purchase shares of Guardian Pharmacy Services via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Guardian Pharmacy Services shares.
-
What Is The Guardian Pharmacy Services Share Price Today?
Guardian Pharmacy Services was last trading at $20.14 per share. This represents the most recent stock quote for Guardian Pharmacy Services. Yesterday, Guardian Pharmacy Services closed at $20.32 per share.
-
How To Buy Guardian Pharmacy Services Stock Online?
In order to purchase Guardian Pharmacy Services stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 0.67% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is up 3.79% over the past day.
Buy
67
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 12.45% over the past day.
